High sensitive immunophenotyping and DNA ploidy techniques for minimal residual disease investigation in multiple myeloma.

被引：0
|
作者：
Almeida, J
Orfao, A
Ocqueteau, M
Mateo, G
Corral, M
Caballero, D
Blade, J
San Miguel, JF
机构：
[1] Univ Hosp, Hematol Serv, Dept Med, Univ Salamanca, Salamanca, Spain
[2] Hosp Clin, Barcelona, Spain
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
401
引用
收藏
页码：98A / 98A
页数：1
相关论文
共 50 条
  • [21] Multiple myeloma, immunotherapy and minimal residual disease
    Kusenda, J.
    Kovarikova, A.
    NEOPLASMA, 2016, 63 (05) : 651 - 658
  • [22] Minimal residual disease monitoring in multiple myeloma
    Davies, FE
    Rawstron, RC
    Owen, RG
    Morgan, GJ
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (01) : 197 - 222
  • [23] Standardisation of minimal residual disease in multiple myeloma
    Innao, V.
    Allegra, A.
    Russo, S.
    Gerace, D.
    Vaddinelli, D.
    Alonci, A.
    Allegra, A. G.
    Musolino, C.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
  • [24] Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma
    Schinke, Carolina
    Deshpande, Shayu
    Mitchell, Alan
    Faham, Malek
    Patel, Purvi
    Thanendrarajan, Sharmilan
    Mohan, Meera
    Mathur, Pankaj
    Matin, Aasiya
    Radhakrishnar, Muthukumar
    Tytarenko, Ruslana
    Stephens, Owen W.
    van Rhee, Frits
    Zangari, Maurizio
    Jethava, Yogesh
    Petty, Nathan
    Alapat, Daisy V.
    Johnson, Sarah K.
    Epstein, Joshua
    Barlogie, Bart
    Davies, Faith E.
    Heuck, Christoph
    Hoering, Antje
    Weinhold, Niels
    Morgan, Gareth J.
    BLOOD, 2015, 126 (23)
  • [25] Minimal residual disease (MRD) investigation in multiple myeloma - hype or real progress?
    Hose, D.
    Seckinger, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 244 - 245
  • [26] Real-world sustained minimal residual disease (MRD) negativity using NGS in multiple myeloma.
    Demaree, Audrey
    Hewitt, Anthony
    Lee, Lik Wee
    Eckert, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Sensitive and specific DNA and RNA sequencing techniques for detecting minimal residual disease
    Crowgey, Erin L.
    Mahajan, Nitin
    Wong, Wing H.
    Kolb, Edward A.
    Druley, Todd
    CANCER RESEARCH, 2017, 77
  • [28] Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM)
    Flores-Montero, Juan A.
    Paiva, Bruno
    Sanoja-Flores, Luzalba
    Puig, Noemi
    Garcia, Omar
    Boettcher, Sebastian
    Perez-Moran, Jose J.
    Belen Vidriales, Maria
    Mateos, Maria-Victoria
    Garcia-Sanz, Ramon
    Jimenez, Cristina
    Gonzalez, Marcos
    Martinez-Lopez, Joaquin
    Consuelo Canizo, Maria
    San Miguel, Jesus
    Durie, Brian
    van Dongen, Jacques J. M.
    Orfao, Alberto
    BLOOD, 2015, 126 (23)
  • [29] Minimal residual disease in multiple myeloma: current status
    Ding, Hong
    Xu, Juan
    Lin, Zhimei
    Huang, Jingcao
    Wang, Fangfang
    Yang, Yan
    Cui, Yushan
    Luo, Hongmei
    Gao, Yuhan
    Zhai, Xinyu
    Pang, Weicui
    Zhang, Li
    Zheng, Yuhuan
    BIOMARKER RESEARCH, 2021, 9 (01)
  • [30] Advances in minimal residual disease monitoring in multiple myeloma
    Wijnands, Charissa
    Noori, Somayya
    van de Donk, Niels W. C. J.
    VanDuijn, Martijn M.
    Jacobs, Joannes F. M.
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2023, 60 (07) : 518 - 534
12345